Targeted Prostate Cancer Screening in Carriers of BRCA1 or BRCA2 Pathogenic Germline Variants Detects Clinically Relevant Disease: 5-year Results from the IMPACT Study

EK Bancroft; EC Page; J McHugh; S Thomas; N Taylor; J Pope; DG Evans; J Rothwell; EM Grindedal; L Maehle; P James; J McKinley; L Mascarenhas; L Side; T Thomas; ME van Leerdam; CJ van Asperen; LALM Kiemeney; J Ringelberg; M Vlaming; K Rønlund; PJS Osther; BT Helfand; CG Hutten; RA Oldenburg; C Cybulski; D Wokolorczyk; KR Ong; C Huber; M Salinas; L Feliubadaló; JC Oosterwijk; WAG van Zelst-Stams; J Cook; DJ Rosario; K Maxwell; J Powers; S Buys; J Lyman; MGEM Ausems; RK Schmutzler; K Rhiem; L Izatt; V Tripathi; MR Teixeira; M Cardoso; WD Foulkes; A Aprikian; R Davidson; M Longmuir; MWG Ruijs; EW Blom; K van Engelen; R Williams; L Andrews; DG Murphy; S Saya; D Halliday; L Walker; A Liljegren; S Carlsson; A Azzabi; I Jobson; K Snape; M Gowie; M Harris; M Tischkowitz; A Taylor; J Kirk; R Susman; R Chen-Shtoyerman; A Spigelman; N Pachter; M Ahmed; TRY Cajal; M Krajc; R Cleaver; M Cruellas; E Perez-Ballestero; AF Brady; D Gallagher; A Donaldson; J Barwell; N Nicolai; E Friedman; MJ Hall; L Greenhalgh; V Murthy; L Copakova; JS McGrath; P Cooke; B Arun; K Myhill; M Hogben; S Hussain; NK Aaronson; A Ardern-Jones; CH Bangma; E Castro; D Dearnaley

Journal article

Targeted Prostate Cancer Screening in Carriers of BRCA1 or BRCA2 Pathogenic Germline Variants Detects Clinically Relevant Disease: 5-year Results from the IMPACT Study

EK Bancroft, EC Page, J McHugh, S Thomas, N Taylor, J Pope, DG Evans, J Rothwell, EM Grindedal, L Maehle, P James, J McKinley, L Mascarenhas, L Side, T Thomas, ME van Leerdam, CJ van Asperen, LALM Kiemeney, J Ringelberg, M Vlaming Show all

European Urology | Published : 2026

DOI: 10.1016/j.eururo.2026.01.031

Open access

Abstract

Background and objective BRCA1 and BRCA2 pathogenic germline variants (PGVs) are associated with higher risk of prostate cancer (PC). The IMPACT study evaluated the utility of targeted prostate-specific antigen (PSA) screening in BRCA1 / BRCA2 PGV carriers. Here we report outcomes after five rounds of PSA screening in IMPACT. Methods Between 2005 and 2015, 3063 participants aged 40–69 yr (median 54 yr) were recruited from 65 centres in 20 countries in two cohorts: (1) BRCA1 / BRCA2 PGV carriers (915 BRCA1 , 901 BRCA2 ); and (2) age-matched noncarriers for a familial PGV (727 BRCA1 and 520 BRCA2 noncarriers). Annual PSA screening was performed, with PSA >3.0 ng/ml used as the indication for p..

View full abstract